Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial
NCT00649792
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
214
Enrollment
INDUSTRY
Sponsor class
Conditions
Multiple Sclerosis
Interventions
DRUG:
Fampridine-SR
Sponsor
Acorda Therapeutics